

TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED

(Company Registration No. 91120000103100784F)

(Incorporated in People's Republic of China)

UPDATE ON CHANGE OF COMPANY NAME

— COMPLETION OF THE INDUSTRIAL AND COMMERCIAL REGISTRATION

The board of directors (the “Board”) and every individual director of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the “Company”) hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

The Board refers to the annexure to the notice of the annual general meeting of the Company for the financial year ended 31 December 2021 (“**FY2021**”) (the “**2022 AGM**”) dated 22 April 2022 relating to the proposed change of the Chinese name of the Company from “天津中新药业集团股份有限公司” to “津药达仁堂集团股份有限公司”, and the proposed change of the English name of the Company from “Tianjin Zhong Xin Pharmaceutical Group Corporation Limited” to “Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited” (the “**Proposed Change of Company Name**”), and consequential amendments to the Articles of Association of the Company in relation to the Proposed Change of Company Name and the application for changes in the industrial and commercial registration (as set out on pages 194 to 206 of the Company's annual report for FY2021) (the “**Annexure**”).

Unless otherwise defined, all capitalised terms used herein shall bear the same meanings ascribed to them in the Annexure.

The Company had on 22 April 2022 duly convened its 2nd board meeting for the financial year ending 31 December 2022, at which the Board considered and approved the Proposed Change of Company Name. On 16 May 2022, the Company duly convened its 2022 AGM and the Shareholders had at the 2022 AGM considered and approved, amongst others, the Proposed Change of Company Name. Please refer to the Annexure and the announcement dated 16 May 2022 made by the Company in relation to the poll results of the 2022 AGM held on 16 May 2022 for further details.

Further to the 2022 AGM where the resolution relating to the Proposed Change of Company Name was duly passed, in accordance with the applicable laws and regulations and the Articles of Association of the Company, upon application by the Company to the Tianjin Administration for Market Regulation (天津市市场监督管理委员会) (the “**TAMR**”) to update the industrial and commercial registration details pertaining to the Company which has been completed on 18 May 2022, the TAMR has issued a new business license (营业执照) to the Company (the “**New Business License**”) to confirm that the Chinese name of the Company is now “津药达仁堂集团股份有限公司”. As stated in the Annexure, there is no requirement for the registration of the English name of the Company with any competent authority in the PRC. Accordingly, the Proposed Change of Company Name is effective from 18 May 2022. The details of the New Business License are set out below.

统一社会信用代码 : 91120000103100784F
Uniform social credit No.

企业名称 : 津药达仁堂集团股份有限公司
Name of company : Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

类型 : 股份有限公司 (上市)
Type : Joint stock company (listed)

住 所 : 天津市南开区白堤路 17 号
Domicile : 17 Baidi Road, Nankai District, Tianjin

法定代表人 : 张铭芮
Legal representative : Zhang Mingrui

注册资本 : 773,443,076元人民币
Registered capital : RMB773,443,076

成立日期 : 1981年12月29日
Date of incorporation : 29 December 1981

营业期限 : 1981年12月29日至2050年1月1日
Business term : From 29 December 1981 to 1 January 2050

经营范围 : 中药材、中成药、中药饮片、西药制剂、化学药品原药制造(3810)化学药品制剂、新草药、医疗器械、营养保健品、化学试剂加工、制造、批发、零售；中药外配加工；卫生用品、健身器材、生活及环境卫生用消毒用品、药物护肤产品、日用百货、服装、鞋帽、家用电器、日用杂品批发、零售；仓储、宣传广告、技术开发、转让、经济信息咨询服务、房屋租赁；计算机及软件、分析仪器的代购、代销、批发、零售；计划生育用品零售；药用设施租赁；经营本企业自产产品及技术的进出口业务；经营本企业生产所需的原辅材料、仪器仪表、机械设备、零配件及技术的进口业务（国有限定公司经营和国家禁止进出口的商品及技术除外）；经营进料加工和“三来一补”业务；中药材收购；下列项目由分支机构经营：医疗包装材料、畜用药、饵料添加剂、饲料、饵料、畜禽药品制造、饲料添加剂制造、牲畜饲养、淡水动植物养殖、餐饮、会议服务；定型包装食品、食用油、副食、调料零售；纯净水、卫生用品制造；定型包装饮用水；瓶装纯净水生产经营；饮料；固体饮料；茶饮料生产经营；限分支机构经营：抗生素、生化药品的销售；限分支机构经营：诊疗科目：医学检验科、中医科、内科专业、儿科专业、皮肤科专业、针灸科专业、生物制品、诊断药品、二类精神药品制剂销售；包装印刷；道路运输；酒（黄酒、酒精）糖、茶、饮料品、蜂产品代购、代销；麻醉药品（罂粟壳）；医疗用毒性药品；蛋白质同化剂；肽类激素的批发；食品、预包装食品、散装食品销售；生物工程及生物制品、化工产品（危险品除外）的研究开发与销售；保健食品批发经营（片剂

类、硬胶囊类、袋泡茶类、口服液类)；食用农产品批发、零售；科学研究和技术服务业（依法须经批准的项目，经相关部门批准后方可开展经营活动）

Manufacturing of traditional Chinese medicinal materials, Chinese patent medicines, traditional Chinese medicine decoction pieces, western medicine preparations and chemical raw materials (3810); processing, manufacturing, wholesale and retail of chemical medicine preparations, new herbal medicines, medical apparatus and instruments, nutritional and healthcare products and chemical reagents; processing and other logistics in relation to traditional Chinese medicinal products; wholesale and retail of hygienic products, gymnastic equipment, disinfection supplies for daily life and environment hygiene, skin protection medical products, general merchandise, clothes, shoes and hats, household appliances and daily sundries; storage, advertising, technology development and transfer, economic information consultation service, house renting; purchases and sales through agents, wholesale, and retail of computers, software, and analytical instruments; retail of family planning supplies; renting of medical equipment; exports of self-produced products and technologies; imports of feedstock, supplementary raw material, apparatus and instruments, machinery equipment, spare parts and corresponding technologies for the production of the Company (except for commodities and technologies which are prohibited to be imported or exported by the PRC government or the sale and/or operation of which are limited to state-owned enterprises); business of processing with imported materials and forms of OEM and compensation trades; purchases of traditional Chinese medicinal materials. The following business items are to be conducted/operated by branches/subsidiaries of the Company: medical packaging material, veterinary, bait additives, feed, bait, production of drugs for livestock, production of feed additives, livestock breeding, freshwater animal breeding and planting, catering, conference services; retail of standard packaged food, edible oil, non-staple food, seasonings; manufacturing of purified water and hygienic products; standard packaged drinking water; production and sales of bottled water; beverage; powder drinks, production and sales of tea drinks; Operation limited only to branches/subsidiaries of the Company: sales of antibiotics and bio-medicines and chemical medicines; Operation limited only to branches/subsidiaries of the Company: medical diagnoses and treatment departments: medical laboratory, traditional Chinese medicine, internal medicine, pediatrics, dermatology, acupuncture, biological products, diagnostic drugs, sales of Class II psychotropic drug preparations; packaging and printing; road transportation; purchases and sales through agents, wholesale and retail of wines (yellow rice wine and alcohol), sugar, tea, beverage and bee products; narcotic drug (only limited to pericarpium papaveris); toxic drugs for medical use; protein assimilation agent; wholesale of peptide hormone; sales of food, pre-packaged food, unpacked food; research, development, and sales of biological engineering and

biological products, chemical products (except for dangerous goods); wholesale of health food (tablets, hard gelatine capsules, teabag, oral use); wholesale and retail of edible agricultural products; scientific research and technical services (for items subject to approval pursuant to applicable laws, the business activities shall be carried out only after obtaining approval from the relevant authorities)

Shareholders should note that the details of the New Business License are written in Chinese language only and the English translation thereof as set out above (save for the English name of the Company) are intended to be for reference only. In case of any discrepancy, the Chinese version shall prevail.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
19 May 2022